Journal article icon

Journal article

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Abstract:

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbation...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1708208

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Oxford college:
St Edmund Hall
Role:
Author
ORCID:
0000-0002-4288-5973
Expand authors...
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England journal of medicine Journal website
Volume:
377
Issue:
17
Pages:
1613-1629
Publication date:
2017-09-12
Acceptance date:
2017-07-14
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pmid:
28893134
Source identifiers:
730192

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP